[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537249":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":30,"responsibleParty":49,"collaborators":7,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":7,"enrollmentInfo":62,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Walter Reed National Military Medical Center","FED",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Teprotumumab Injection [Tepezza]","IGF1 monoclonal antibody",[14],"Tepezza TM",[16],{"name":17,"affiliation":5,"role":18},"Thanh D Hoang, DO","PRINCIPAL_INVESTIGATOR",[20,26],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"THANH D HOANG, DO","CONTACT","3012955165","6220","thanh.d.hoang.mil@health.mil",{"name":27,"role":22,"phone":28,"phoneExt":7,"email":29},"Iris Morris, PhD","3013194599","iris.e.morris3.civ@health.mil",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Bethesda","Maryland","20889","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-77.10026,38.98067,{"lat":42,"lon":41},[45,47],{"name":17,"role":22,"phone":46,"phoneExt":24,"email":25},"301-295-5165",{"name":48,"role":22,"phone":28,"phoneExt":7,"email":29},"Iris E Morris, PhD",{"type":18,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Thanh Hoang","Endocrinologist","100537249","the-effect-of-teprotumumab-on-thyroid-eye-disease-and-thyroid-dysfunction-100537249",false,"NCT06275373","The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction","Teprotumumab","Inclusion Criteria:\n\n* only DOD beneficiaries\n* adult patients 18 years of age or older\n* adult patients with proptosis, ocular\u002Forbital pain, diplopia, lid\u002Forbital edema, or lid\u002Forbital erythema associated with autoimmune thyroid disease\n\nExclusion Criteria:\n\n* Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation\n* patients with a history of uncontrolled diabetes mellitus\n* patients with a history\u002Fdiagnosis of uncontrolled inflammatory bowel disease\n* patients under age 18 years\n* patients who are pregnant or trying to become pregnant.",true,"ALL","18 Years",{"count":63,"type":64},100,"ESTIMATED","OBSERVATIONAL","This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid\u002Forbital edema, or lid\u002Forbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).",[68,69,70],"Thyroid Eye Disease","Graves Ophthalmopathy","Graves Disease",[72,73,74],"Thyroid eye disease","Graves ophthalmopathy","Graves disease","2024-02-16",{"date":77,"type":78},"2024-02-23","ACTUAL",{"date":80,"type":78},"2021-05-12",{"date":82,"type":64},"2027-12-12",{"name":5,"class":6},1]